Thinly traded nano cap Neovasc (NASDAQ:NVCN) is up 66% premarket in reaction to the filing of a U.S. marketing application for its Neovasc Reducer for the treatment of refractory angina. The submission includes a request for an advisory committee meeting.
The device was CE Mark’d in November 2011.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.